Accessibility Menu
Molecular Partners Ag logo

Molecular Partners Ag(OTC) MLLCF

Market Cap$142.54MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)-83%
5 Year-79%
1 Year-10%
1 Month-22%
$3.80
+0%
+0.00Today
Molecular Partners Ag last closing stock price
MetricPriceDate
Last closeUSD 3.802026-07-07
Molecular Partners Ag stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+5.56%USD 3.602026-06-23
1 month-21.65%USD 4.852026-05-28
3 month-5.71%USD 4.032026-04-07
Year to date+8.57%USD 3.502025-12-23
1 year-9.95%USD 4.222025-04-25
3 year-39.2%USD 6.252023-07-05
5 year-79.37%USD 18.422021-07-08
Since inception-83.19%USD 22.602018-06-15

Molecular Partners Ag Financials at a Glance

Market Cap

$142.54MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CHF 0.00

Net Income (TTM)

-CHF 58.07M

EPS (TTM)

-$1.93

P/E Ratio

-1.97

Dividend

$0.00

Beta (Volatility)

0.39 (Low)

Price

$3.80

Volume

3,534

Open

$3.84

Previous Close

$3.80

Daily Range

$3.80 - $3.84

52-Week Range

$2.25 - $4.85

Estimated Earnings Date

Aug 25, 2026

MLLCF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Molecular Partners Ag

Molecular Partners AG is a clinical-stage biotechnology company focused on developing innovative therapeutics using designed ankyrin repeat proteins (DARPins) for oncology treatments. The company is headquartered in Schlieren, Switzerland, and has a robust pipeline of candidates in various stages of clinical trials.

Products and Services
  • MP0317: Phase 2 trial for advanced solid tumors
  • MP053: Phase 1 trial for acute myeloid leukemia
  • MP0712: Phase 1 trial targeting DLL3 in SCLC and neuroendocrine tumors
Growth Outlook
  • Strong pipeline with multiple candidates in clinical trials
  • Collaboration with Orano Med SAS for novel Radio-DARPin therapeutics
  • Potential market expansion in oncology with innovative therapies
Financial Highlights
  • Cash and short-term investments of approximately $78.96 million
  • Current ratio of 9.42 indicates strong liquidity position
  • Net income for Q1 2026 was -$13.18 million, reflecting ongoing R&D investments
Molecular Partners AG is positioned in the biotechnology sector, focusing on the development of targeted therapies for cancer treatment. The company's innovative approach using DARPins offers a unique mechanism of action, potentially leading to more effective treatments with fewer side effects. The ongoing clinical trials and collaborations with established partners highlight the company's commitment to advancing its product pipeline. Financially, the company maintains a strong liquidity position, as evidenced by its current ratio, which suggests it can cover its short-term liabilities comfortably. Despite reporting net losses, the significant investments in research and development are indicative of a long-term growth strategy aimed at bringing novel therapies to market. The collaboration agreements further enhance the potential for future revenue streams, making Molecular Partners AG an intriguing option for investors interested in the biotechnology space.
AI Generated • Jul 2, 2026

Industry

Biotechnology

Sector

Health Care

Employees

149

CEO

Patrick Amstutz, PhD

Website

www.molecularpartners.com

Headquarters

Schlieren, ZH 8952, CH

MLLCF Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-66.19%

Return on Capital

-66.01%

Return on Assets

-66.25%

Earnings Yield

-50.76%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$142.54MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

37.51M

Volume

3.53K

Avg. Volume

75.548

Financials (TTM)

Gross Profit

-CHF 10.04M

Operating Income

-CHF 55.51M

EBITDA

-CHF 56.24M

Operating Cash Flow

-CHF 47.99M

Capital Expenditure

-CHF 266.07K

Free Cash Flow

-CHF 48.25M

Cash & ST Invst.

CHF 78.96M

Total Debt

CHF 3.35M

Molecular Partners Ag Performance Analysis

Molecular Partners Ag annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CHF 198,520,4951760.8%
20232023-12-31CHF 7,831,732-96.1%
20242024-12-31CHF 5,643,446-27.9%
20252025-12-31CHF 0N/A
Molecular Partners Ag sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Molecular Partners Ag annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CHF 3.71N/A
20232023-12-31CHF -2.10N/A
20242024-12-31CHF -1.80-14.3%
20252025-12-31CHF -1.9910.5%
Molecular Partners Ag sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-24.4%
Q32025-09-3042.9%
Q42025-12-31-6.3%
Q12026-03-31-2.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

CHF 0.00

N/A

Gross Profit

-CHF 502.23K

+19.5%

Gross Margin

0.00%

N/A

Market Cap

$142.54MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.06M

N/A

Employees

134

N/A

Net Income

-CHF 13.18M

+21.4%

EBITDA

-CHF 12.97M

+20.0%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

CHF 78.96M

-39.7%

Total Debt

CHF 3.35M

+56.6%

Accounts Receivable

CHF 2.32M

-41.7%

Inventory

CHF 0.00

N/A

Long Term Debt

CHF 2.14M

+132.5%

Short Term Debt

CHF 1.21M

-1.0%

Return on Assets

-66.25%

N/A

Return on Invested Capital

-70.20%

N/A

Free Cash Flow

-CHF 14.19M

+19.1%

Operating Cash Flow

-CHF 14.19M

+16.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SCNLFScancell Holdings plc
$0.13+0.00%
NDTPNDT Pharmaceuticals Inc.
$0.55+22.22%
JWCTFJW (Cayman) Therapeutics Co. Ltd
$0.20+0.00%
AAWHAscend Wellness Holdings, Inc.
$0.40+2.56%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$8.41-0.06%
TAT&T
$23.94-0.03%
SMRNuScale Power
$7.59-0.08%
ORCLOracle
$117.74-0.02%

Questions About MLLCF

What is the current price of Molecular Partners Ag?

Molecular Partners Ag is trading at $3.80 per share.

What is the 52-week range for Molecular Partners Ag?

Over the past 52 weeks, Molecular Partners Ag has traded between $2.25 and $4.85.

How much debt does Molecular Partners Ag have?

As of the most recent reporting period, Molecular Partners Ag reported total debt of CHF 4.16M.

How much cash does Molecular Partners Ag have on hand?

Molecular Partners Ag reported CHF 98.03M in cash and cash equivalents in its most recent financial results.

What is Molecular Partners Ag’s dividend yield?

Molecular Partners Ag does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services